MISSISSAUGA, on, July 29, 2020 (world news) — BioSyent Inc. Today (“BioSyent”, the “company”, TSX venture: RX) announced the canadian launch and availability of the product on Tibella® (tibolone) for short-term treatment of vasomotor symptoms caused by a deficiency of estrogen in postmenopausal women more than one year after menopause. Tibella® display differential tissue-specific effects that are responsible for weak estrogenic and progestational properties as well as some androgenic effects. Tibella® should be prescribed only for women with intact uterus after treatment involves progestogenic activity.
“Tibella® established safety profile and effectiveness worldwide there are already more than 30 years to treat menopause symptoms. Tibella® it has been shown to reduce bothersome symptoms such as hot flashes and sweating,” said Dr. Robert Reid, MD, a gynecologist and Professor of obstetrics and gynecology, Queen’s University, Queen’s University in Kingston, Ontario.
Most women experience menopause after the age of 45. Approximately 60% to 80% of women will experience vasomotor symptoms of menopause. In Canada, almost 4 million women aged 45 to 59 years passed or will soon go through menopause. Up to 80% of women can experience at least one of the symptoms of menopause, including mood swings, irritability, interrupted sleep or hot flashes.
Dr. Christine Derzko, associate Professor of internal medicine, division of endocrinology at the University of Toronto said that “women suffer from vasomotor symptoms for many years, and it is important to have more options available for treatment. Having Tibella® available in Canada provides us the opportunity and benefits canadian women.”
Tibella® delivery in a month began.
“We are pleased to introduce this safe and effective treatment for canadian women who suffer from vasomotor symptoms of menopause,” said rené Goehrum, President and CEO of BioSyent. Mr. Goehrum continued: “Tibella® now available at pharmacies for canadian women. Tibella® this is the newest addition to the portfolio of women’s health BioSyent which include FeraMAX® for the prevention and treatment of iron deficiency anemia and RepaGyn® which relieves dryness and promotes healing of the vaginal mucosa. We strive to further expand our canadian business with the subsequent launches of the product and continuing to collect a wide range of products that serve unmet medical needs.”
François Fornieri, CEO of women’s health mitre, commented, “We are very proud that our product was launched as Tibella® in Canada BioSyent on our partner. We are pleased to provide canadian doctors and women with a long-awaited treatment option to safely and effectively eliminate the symptoms of menopause”.
Tibella® designed and manufactured by Mithra pharmaceuticals. Tibella® is a registered trademark of BioSyent Pharma Inc.
Monograph Product Tibella, May 2019. https://pdf.hres.ca/dpd_pm/00051104.PDF
The society of obstetricians and gynecologists of Canada. www.menopauseandu.ca
Canadian Society Of Menopause. www.sigmamenopause.com
Statistics Canada: population by sex and age group: 2019 census data.
About BioSyent Inc.
Listed on the TSX venture exchange under the trading symbol “RX”, BioSyent is a profitable growth oriented specialty pharmaceutical company focused on the licensing or acquisition of innovative pharmaceutical and other medical products that are successfully developed, are safe and effective and have a proven track record of improving the lives of patients. BioSyent supports professionals in the health field who treat these patients, selling their products through their communities, hospitals and international business units.
As at the date of this press release, the company 12,808,170 common shares.
For a direct quote of the market for the TSX venture exchange and other company financial information please visit www.tmxmoney.com.
For more information contact:
This press release may contain information or statements that are predictive. The contents herein represent our judgment as of the release date, and are subject to risks and uncertainties that could cause actual results or outcomes may differ materially from the forecast information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, revenue, operations, profitability and receipt of regulatory approvals.
Neither TSX venture exchange nor its regulation services provider (as that term is defined in the policies of the TSX venture exchange) accepts responsibility for the adequacy or accuracy of this press release.